TY - JOUR
T1 - Serologic versus molecular testing for screening for hepatitis C virus infection in patients with hematologic malignancies
AU - Torres, Harrys A.
AU - Angelidakis, Georgios
AU - Jiang, Ying
AU - Economides, Minas
AU - Mustafayev, Khalis
AU - Yibirin, Marcel
AU - Orlowski, Robert
AU - Champlin, Richard
AU - Verstovsek, Srdan
AU - Raad, Issam
N1 - Funding Information:
Investigator-initiated study sponsored by Merck & Co., Inc. Also supported in part by the National Cancer Institute under award number P30CA016672, which supports the MD Anderson Cancer Center Clinical Trials Support Resource.
Funding Information:
Dr. Torres is or has been the principal investigator for research grants from the National Cancer Institute, Gilead Sciences and Merck & Co., Inc., with all funds paid to the MD Anderson Cancer Center. Dr. Torres is or has been a paid scientific advisor for AbbVie, Inc., Gilead Sciences, Merck & Co., Inc., and Dynavax Technologies; the terms of these arrangements are being managed by MD Anderson Cancer Center in accordance with its conflict-of-interest policies. All other authors declare no competing interests.
Publisher Copyright:
© Copyright 2022 the Author(s).
PY - 2022/9/16
Y1 - 2022/9/16
N2 - Testing for antibody against hepatitis C virus (anti-HCV) is a low-cost diagnostic method worldwide; however, an optimal screening test for HCV in patients with cancer has not been established. We sought to identify an appropriate screening test for HCV infection in patients with hematologic malignancies and/or hematopoietic cell transplants (HCT). Patients in our center were simultaneously screened using serological (anti-HCV) and molecular (HCV RNA) assays (February 2019-November 2019). In total, 214 patients were enrolled in this study. Three patients (1.4%) were positive for anti-HCV, and 2 (0.9%) were positive for HCV RNA. The overall percentage agreement was 99.5% (95% CI: 97.4-99.9). There were no cases of seronegative HCV virus infection. The positive percentage agreement was 66.7% (95% CI: 20.8-93.9), and the negative percentage agreement was 100.0% (95% CI: 98.2-100.0). Cohen kappa coefficient was 0.80 (95% CI: 0.41-1.00, P <.0001). The diagnostic yield of screening for chronic HCV infection in patients with cancer is similar for serologic and molecular testing.
AB - Testing for antibody against hepatitis C virus (anti-HCV) is a low-cost diagnostic method worldwide; however, an optimal screening test for HCV in patients with cancer has not been established. We sought to identify an appropriate screening test for HCV infection in patients with hematologic malignancies and/or hematopoietic cell transplants (HCT). Patients in our center were simultaneously screened using serological (anti-HCV) and molecular (HCV RNA) assays (February 2019-November 2019). In total, 214 patients were enrolled in this study. Three patients (1.4%) were positive for anti-HCV, and 2 (0.9%) were positive for HCV RNA. The overall percentage agreement was 99.5% (95% CI: 97.4-99.9). There were no cases of seronegative HCV virus infection. The positive percentage agreement was 66.7% (95% CI: 20.8-93.9), and the negative percentage agreement was 100.0% (95% CI: 98.2-100.0). Cohen kappa coefficient was 0.80 (95% CI: 0.41-1.00, P <.0001). The diagnostic yield of screening for chronic HCV infection in patients with cancer is similar for serologic and molecular testing.
UR - http://www.scopus.com/inward/record.url?scp=85138171785&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138171785&partnerID=8YFLogxK
U2 - 10.1097/MD.0000000000030608
DO - 10.1097/MD.0000000000030608
M3 - Article
C2 - 36123927
AN - SCOPUS:85138171785
SN - 0025-7974
VL - 101
SP - E30608
JO - Medicine (United States)
JF - Medicine (United States)
IS - 37
ER -